Cilcare is proud to announce that its breakthrough compound, CIL001, has been named the winner in the Therapeutics category at the 5th Annual Hearing Technology Innovator Awards™, hosted by Hearing Health & Technology Matters.
This prestigious recognition celebrates the innovative potential of CIL001, a first-in-class drug candidate designed to treat cochlear synaptopathy, a leading cause of age-related hearing loss, often referred to as “hidden hearing loss.” This condition affects millions worldwide and is characterized by difficulty hearing in noisy environments—an issue for which there is currently no approved treatment.
CIL001 is set to enter Phase 2 clinical trials in 2025, following promising preclinical results that demonstrate its ability to address cochlear synaptopathy. With an innovative long-lasting formulation, CIL001 will be administered via a single transtympanic injection, offering a transformative approach to hearing loss treatment.
This recognition highlights CILcare’s unwavering dedication to advancing therapies for hearing disorders, reinforcing the company’s position as a leader in hearing healthcare innovation.
We extend our heartfelt thanks to the Hearing Technology Innovator Awards™ organizers, the judging panel, and all the fellow innovators who continue to push the boundaries of hearing technology.
For more information on CIL001 and Cilcare’s pipeline, click here.
